EpiCast Report: Acute Coronary Syndrome (ACS) – Epidemiology Forecast to 2022, New Report Launched

Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will be a significant public health problem as the elderly population increases around the world. ACS is classified into three disease entities based on evidence of heart muscle damage inferred from a person’s symptoms, changes in the ST-tracing of the electrocardiogram (ECG), and levels of cardiac biomarkers that signify heart muscle death: ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA). These three disease entities differ in their clinical characteristics, treatment approaches, and survival probabilities.

The epidemiology of ACS in the 7MM has changed significantly during the past two decades and varies between the western and Japanese markets. In order to capture the country-specific trends and provide detailed patient population segmentation, epidemiologists built separate forecasts for (myocardial infarction) (MI) and UA in the 7MM and used a case-flow methodology to determine the number of cases that survived until hospital discharge and for one year after hospital discharge.

The epidemiologists forecast that in the 7MM, the hospitalized incident cases of ACS will increase from 1.29 million cases in 2012 to 1.43 million cases in 2022 at the rate of 1.04% per year. The US constitutes around 40% of the total hospitalized incident ACS cases in the 7MM and will be the market with the highest number of cases during the forecast period. The majority of the cases occurred in men (58.15%) and in those ages =65 years (69.01%). For the 7MM, about 33% of the ACS cases were STEMI, 44% were NSTEMI, and 23% were UA. The proportions varied depending on the market.

Scope

The ACS EpiCast Report provides an overview of the ACS risk factors and comorbidities, a discussion of the ACS global and historical trends, and a 10-year epidemiological patient forecast for ACS from 2012 to 2022 in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). The epidemiological patient forecast includes –

  • Hospitalized incident cases of ACS, segmented by STEMI, NSTEMI, and UA
  • ACS cases that survived until hospital discharge, segmented by STEMI, NSTEMI, and UA
  • ACS cases that survived for one year post-hospital discharge, segmented by STEMI, NSTEMI, and UA
  • Diagnosed prevalent cases of myocardial infarction (MI) segmented by STEMI and NSTEMI from 2012 to 2022 in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK)
  • The ACS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global ACS market.
  • Quantify patient populations in the global ACS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the patient segmentations that present the best opportunities for ACS therapeutics in each of the markets covered.
  • Identify the number of ACS cases survived to key time periods.

Spanning over 108 pages, 21 Tables and 19 Figures, EpiCast Report: Acute Coronary Syndrome (ACS) – Epidemiology Forecast to 2022” report covering Introduction, Epidemiology, Appendix.

Inquire about this report: http://www.marketresearchreports.com/globaldata/epicast-report-acute-coronary-syndrome-acs-epidemiology-forecast-2022

About Market Research Reports, Inc.

Market Research Reports,Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

MarketResearchReports.com: Acute Coronary Syndrome – Pipeline Review, H2 2013, New Report Launched

Acute Coronary Syndrome – Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report reviews key players involved in the therapeutic development for Acute Coronary Syndrome. Acute Coronary Syndrome Pipeline Review, Half Year is built using data and information sourced from publisher proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by publisher team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Acute Coronary Syndrome.
  • A review of the Acute Coronary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Acute Coronary Syndrome pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Acute Coronary Syndrome.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Acute Coronary Syndrome pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 114 pages, 31 tables and 12 figures, “Acute Coronary Syndrome – Pipeline Review, H2 2013” report provides information on the therapeutic development for Acute Coronary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects.

In addition to covering the Acute Coronary Syndrome Overview, Late Stage Products, Mid Clinical Stage Products, Early Clinical Stage Products, Discovery and Pre-Clinical Stage Products, Acute Coronary Syndrome Therapeutics – Drug Profile Updates, Acute Coronary Syndrome Therapeutics – Discontinued Products, Acute Coronary Syndrome Therapeutics – Dormant Products, Acute Coronary Syndrome – Product Development Milestones. The report covers 17 companies F. Hoffmann-La Roche Ltd., AstraZeneca PLC, GlaxoSmithKline plc, Pfizer Inc., Bayer AG, Ligand Pharmaceuticals Incorporated, Medicure Inc., Arena Pharmaceuticals, Inc,. CSL Limited, LG Life Sciences, Ltd, Auspex Pharmaceuticals, Viron Therapeutics, Inc., Regado Biosciences, Cerenis Therapeutics SA Lacer, S.A., Lee’s Pharmaceutical Holdings Limited and Ampio Pharmaceuticals, Inc.

Find all Diseases market research reports under a single page at: Diseases Market Research Reports

About Market Research Reports, Inc.

Market Research Reports, Inc. (www.MarketResearchReports.com) is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.